BTIG Affirms Avinger (AVGR) at 'Buy'; Cuts PT to $6 Amid Q2 Numbers, Financing
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
BTIG lowers its price target on Buy-rated Avinger, Inc. (Nasdaq: AVGR) from $18 down to $6 amid recent Q2 results and financing agreements.
Analyst Sean Lavin commented,
Our updated rev estimates have nothing to do with AVGR’s financing, which was needed and de-risks AVGR some. We would have updated our model earlier but were not able to thus we are publishing now. After Q2, we set out to better understand the issues impacting sales. The general feedback we received from a very active user who speaks to other users was imaging has the potential to make artherectomy safer and more effective, but the device is not ready for commercial prime time. He said issues with the fibers and illumination are becoming less frequent, but now it is appropriate for thought leaders willing to take extra time to be early publishers, but it is not ready for the average doctor who just wants things to work so he can get in and out of the operating room efficiently. We do not know if AVGR can correct the issues. If they can, we see the stock being a potential home run from here. If they cannot, adoption is unlikely.
FY16 revenue estimate moves to $19 million, FY17 is at $29 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Electric (GE) PT Lowered to $35 at UBS Following 4Q Report
- Bristol-Myers Squibb Co. (BMY) PT Lowered to $58 at Barclays
- Zions Bancorp (ZION) PT Raised to $50 at Goldman Sachs
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!